Effect of Baseline or Changes in Adrenergic Activity on Clinical Outcomes in the β-Blocker Evaluation of Survival Trial
Why the study?
Does bucindolol affect death or heart failure hospitalization in patients with chronic heart failure based on baseline or changes in adrenergic activity?
Population
Subjects with chronic heart failure (CHF)
Comparison
Bucindolol vs Placebo
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
Marked sympatholysis may increase mortality risk in HF; hypothesis-generating and should not yet change practice.
Structured PICO
Does bucindolol affect death or heart failure hospitalization in patients with chronic heart failure based on baseline or changes in adrenergic activity?
P
Population
Subjects with chronic heart failure (CHF)
I
Intervention
Bucindolol
C
Comparator
Placebo
O
Outcome
Death or death plus CHF hospitalizationcomposite
In patients with chronic heart failure, marked sympatholysis from bucindolol is associated with an increased risk of death, highlighting a potential adverse effect of profound adrenergic reduction.
Cite This Study
Bristow et al. (2004) studied this question.